News Pfizer targets $2.5bn more in cost savings Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.
News Pfizer cues up vitiligo filing for Litfulo after phase 3 win Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.
News Drugmakers asked to defend Chinese trials; reports The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.
News Ibrance cleared in US for 'double-positive' breast cancer Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.
News Pfizer's Seagen-derived ADC pipeline suffers a setback One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.
News MSD takes on Pfizer's Prevnar with new Capvaxive approval MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.
News TransThera's resistant biliary cancer drug cleared in China TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
